⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MBRX News
Moleculin Biotech, Inc.
Form 8-K
sec.gov
MBRX
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Form 8-K
sec.gov
MBRX
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
globenewswire.com
MBRX
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Form 8-K
sec.gov
MBRX